Anna Landry
Adult Health · Lake Charles, LANPI 1639348394
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 282 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$967
- E.r. Squibb & Sons, L.L.C.$728
- Novartis$686
- Abbott$308
- Boston Scientific$237
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$209
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,925100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 60 | $967 |
| E.r. Squibb & Sons, L.L.C. | 53 | $728 |
| Novartis | 47 | $686 |
| Abbott | 9 | $308 |
| Boston Scientific | 7 | $237 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $209 |
| Johnson & Johnson | 13 | $208 |
| Esperion Therapeutics, Inc. | 13 | $195 |
| Merck | 11 | $184 |
| Novo Nordisk | 9 | $163 |
| Amgen | 10 | $161 |
| AstraZeneca | 10 | $149 |
| Amarin Pharma, Inc. | 5 | $98 |
| Heartflow, Inc. | 1 | $98 |
| Lexicon Pharmaceuticals, Inc. | 4 | $73 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| Silk Road Medical, Inc. | 3 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Boehringer Ingelheim | 3 | $47 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Kestra Medical Technology Services, Inc. | 1 | $35 |
| Impulse Dynamics (USA) Inc. | 1 | $30 |
| Recor Medical Inc | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Bristol Myers Squibb | 1 | $20 |
| Abiomed | 1 | $19 |
| Bayer | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,925 in reported general payments places this provider in the 80th percentile of 203 adult health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 392 | $318,022 |
| XareltoRivaroxaban | 128 | $103,043 |
| CamzyosMavacamten | 12 | $101,807 |
| EntrestoSacubitril/Valsartan | 55 | $49,309 |
| Repatha SureclickEvolocumab | 46 | $29,698 |
| FarxigaDapagliflozin Propanediol | 40 | $23,703 |
| MounjaroTirzepatide | 20 | $20,219 |
| NexlizetBempedoic Acid/Ezetimibe | 19 | $10,920 |
| Metoprolol Succinate | 634 | $8,200 |
| Droxidopa | 11 | $7,731 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,008 |
| Rosuvastatin Calcium | 481 | $6,571 |
| Atorvastatin Calcium | 482 | $4,714 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $3,956 |
| Ranolazine ErRanolazine | 41 | $3,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $967 | $318,022392 claims |
| Johnson & JohnsonXarelto | $208 | $103,043128 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $728 | $101,80712 claims |
| NovartisEntresto | $686 | $49,30955 claims |
| AstraZenecaFarxiga | $149 | $23,70340 claims |
| Esperion Therapeutics, Inc.Nexlizet | $195 | $10,92019 claims |
| Sanofi-aventis U.S. LLCPlavix | $23 | $2,98913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 203 adult health providers in Louisiana.
Other adult health in Lake Charles
- Damika HarmonLake Charles$27K
- Sarah CoolingLake Charles$10K
- Hollie DonnellyLake Charles$9K
- Amanda BurnettLake Charles$9K
- Jennifer GrahamLake Charles$8K
- Kendra MecheLake Charles$6K
- Jared WhiteheadLake Charles$6K
- Rebecca Godare SteinLake Charles$5K
- Jennifer CrawfordLake Charles$5K
- Rachel RowlandLake Charles$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.